Despite the high safety profile demonstrated in clinical trials. the immunogenicity of adeno-associated virus (AAV)-mediated gene therapy remains a major hurdle. Specifically. T-cell-mediated immune responses to AAV vectors are related to loss of efficacy and potential liver toxicities. https://www.mamapaisa.com/product-category/10-31/